A century of research has passed since the discovery and definition of Alzheimer's disease (AD), the primary common dementing disorder worldwide. However, AD lacks definite diagnostic approaches and effective cure at the present. Moreover, the currently available diagnostic tools are not sufficient for an early screening of AD in order to start preventive approaches. Recently the emerging field of nanotechnology has promised new techniques to solve some of the AD challenges. Nanotechnology refers to the techniques of designing and manufacturing nanosize (1-100 nm) structures through controlled positional and/or self-assembly of atoms and molecules. In this report, we present the promises that nanotechnology brings in research on the AD diagnosis and therapy. They include its potential for the better understanding of the AD root cause molecular mechanisms, AD's early diagnoses, and effective treatment. The advances in AD research offered by the atomic force microscopy, single molecule fluorescence microscopy and NanoSIMS microscopy are examined here. In addition, the recently proposed applications of nanotechnology for the early diagnosis of AD including bio-barcode assay, localized surface plasmon resonance nanosensor, quantum dot and nanomechanical cantilever arrays are analyzed. Applications of nanotechnology in AD therapy including neuroprotections against oxidative stress and anti-amyloid therapeutics, neuroregeneration and drug delivery beyond the blood brain barrier (BBB) are discussed and analyzed. All of these applications could improve the treatment approach of AD and other neurodegenerative diseases. The complete cure of AD may become feasible by a combination of nanotechnology and some other novel approaches, like stem cell technology.
INTRODUCTION
Alzheimer's disease (AD), first defined a century ago [2] , is the primary common cause of dementia in the geriatric population [83] . The incidence and prevalence of AD increases with age and as the life expectancy is rising worldwide, AD is quickly becoming one of the pressing universal healthcare problems [127] . Cur- Fig. 1 . During AD, neurons of some brain areas, especially neocortex and limbic system (hippocampus, amygdala and their associated cortices), gradually deteriorate and undergo death. Neocortex is responsible for processing the sensory information relayed to the brain, controlling voluntary movements, performing conscious thought and other mental activities. The Limbic system is mainly responsible for emotions and instinctive behavior. The hippocampus plays important roles in learning and short-term memory.
ory at the onset (also known as mild cognitive impairment (MCI)) to an eventual dementia syndrome [15] . The latter is a severe impairment or loss of intellectual capacity and function including deficits in attention, in memory, in thinking, in reasoning and in language skills [148] . Moreover, accompanied with the dementia syndrome is usually the inability of the patient to perform "motor functions" and "alterations of personality" [84, 148] . On the average, the patient dies nine years after the AD diagnosis [16] .
The pathology of AD is a progressive one in nature. In addition, the minimal repair and regeneration capacity of the brain tissue makes this progressive process almost irreversible [83] . This necessitates a quite early diagnosis and prevention of the disease. The earlier we stop the pathogenetic process, the less the patient will remain symptomatic. Therefore, undertaking precise diagnostic procedures for screening the AD high risk population is the current preferred approach against the disease [90] . However, at the present there is not any single diagnostic tool for precise screening or early and accurate detection of the disease [33, 108] ; and only a probable diagnosis with an 80% confidence, on average, is possible based on clinical criteria (including laboratory tests, neuroimaging and neuropsychological assessment) [33] . Moreover, the commonly prescribed medications are only symptomatic and do not stop the progressive pathology of the disease [83] . Even the latest advanced medications currently available or aimed in some studies can only slow or cease the progress of the disease pathogenesis and are not able to restore the lost brain function. Therefore, AD is an incurable disease at the present [83, 84] .
Nanotechnology encompasses a recent and overwhelming group of atomic-and molecular-based techniques capable of arranging atoms and molecules in specially designed and controlled positions [79, 80] . This capability has facilitated the production of new structures and devices with, at least, one dimension in nanoscale (1-100 nm) [79, 80] . Richard P. Feynman, the Nobel laureate physicist and the pioneer of nanoscale sciences and technology [32] , first envisioned the application of nanotechnology in medicine in 1961. Two decades later K. Eric Drexel, following the idea of molecular engineering and manipulation, postulated the possibility of direct interactions between devices of nanoscale and biological molecules [23] . These interactions have become the basis of new nanomethods for probing molecular changes within cells both for investigational and diagnostic purposes. Moreover, through nanotechnology it is now possible to target therapeutic agents to specific body cells, tissues and organs more effectively and with less adverse consequences.
The importance of medical applications of nanotechnology is more evident in diseases related to the central nervous system (CNS), mainly due to the highly elaborate structural and functional properties of the CNS [124] . Nanotechnology is promising a noninvasive access to this complex system that is not presently achievable by other approaches [56] . In this report, we present nanotechnology methods recently used for basic research on the AD molecular pathogenesis, as well as the potential and known nanotechnology approaches thus far suggested to combat AD, in the areas of diagnosis and therapy [48, 109, 118, 123] .
ALZHEIMER'S DISEASE PATHOLOGY
According to the AD pathology, the neurons of some areas of the brain including neocortex and limbic struc- uct of amyloidogenesis process, the amyloid fibrils (deposited in amyloid plaques), are commonly known as the main actors in the pathology of AD. However, recently some soluble oligomeric and protofibrillar species of amyloidogenesis process have been found to be neurotoxic, as well [17, 37, 67, 139] .
The damage to nerve cells due to oxidative stress is another suspected initial step in the pathogenesis of AD [96] . During the cellular respiration process in the mitochondria, semi-reduced oxygen species (e.g. super oxide and hydrogen peroxide) also referred to as reactive-oxygen species, are produced [145] . Physiologically, certain biochemical processes neutralize the reactive-oxygen (free radical oxygen) species. Oxidative stress occurs because of the imbalance due to the over-production or the slow neutralization of freeradical oxygen [43, 133] .
Nevertheless, the initial source of oxidative stress in AD is rather unknown. Of course, the assumption is that some vitamin deficiencies, including folic acid and vitamin E deficiencies, disrupt the neutralization mechanisms of the free radicals [133] . More interestingly, there are supporting evidences for a dual relation between Aβ formation and oxidative stress, i.e. beside the effect of Aβ on triggering oxidative stress, oxidative stress in turn mediates the aggregation of Aβ, thereby facilitating its oligomerization [145] .
On the other hand, it is hypothesized that oxidative stress can lead to hyperphosphorylation of τ -protein, "a microtubule associated protein". Therefore, we can consider oxidative stress as a link between amyloid toxicity and τ -protein pathology in AD [21] .
The hyperphoshphorylation of τ -protein, regardless of its root cause, is due to dysregulation in phosphorylation/dephosphorylaton signaling pathways [14] . The main physiological role of τ -protein is stabilization of microtubules [6] . Microtubules are the tube-shaped protein structures that form the cytoskeleton of eukaryotic cells in part, as shown in Fig. 4 [115] . Hyperphosphorylated τ -protein results in destabilization of microtubules due to detachment of τ -protein from microtubules [115] . Of course, there are some evidences against the exclusive association between τ -protein hyperphosphorylation and microtubule reduction in AD. According to these evidences, microtubule reduction happens before τ -protein hyperphosphorylation, and it is presumed to be a direct result of oxidative stress [13] .
The subsequent intracellular events of τ -protein hyperphosphorylation are not only due to τ -protein dysfunction but also to its newly gained toxic properties [38] . Moreover, morphologic changes in synapses, because of cytoskeleton breakdown, will compromise the synaptic connections [6] . On the other hand, hyperphosphorylated τ -protein is prone to polymerization, leading to the formation of paired helical filaments (PHF) deposited in the neurofibrillary tangles (NFT) (see Fig. 4 ). We discuss the structural properties of PHF, revealed by AFM, later in this report.
In addition to the above-mentioned mechanisms, there are other mechanisms in the AD pathogenesis [83, [113] [114] [115] [116] , including disruption of neuronal ionic (e.g. iron, copper and calcium ions) homeostasis, disruption of cholesterol homeostasis, neuroinflammation, impairment in neurotransmission and apoptotic cell death [22, 69] . Explanatory discussions over these mechanisms are beyond the scope of this report. mines the feature resolution of images provided by AFM [142] . There are different kinds of probe tips. For example, commercial SFM probes made of "Oxide sharpened silicon tips" (see Fig. 5 ) are useful for scanning biological structures including cells. This application is because of the ability of these tips to combine high power with physical tolerance on a soft sample surface [14] . However, these tips cause major constraints on lateral resolution and their pyramidal shape makes it impossible to access narrow and deep features [14] . Recently, attaching carbon nanotubes (CNT) to the end of silicon tips has been a breakthrough in lateral resolution and imaging deep and narrow features (Fig. 5 ). In addition, MWNTs provide low tip-sample adhesion and therefore gentler imaging [14] . Wong S.S. et al. for the first time took advantage of this scanning probe technology for visualizing Aβ40 protofibril and fibrils. Their results show a 12-30 % increase in resolution when compared with the results using Si tips [142] .
In almost all AFM studies completed so far for amyloid species, the tapping mode of operation of AFM is used [5, 11] . Tapping mode is the choice mode for scanning single macromolecules including proteins [29] . In the contact mode, inevitable immobilization of the sample to a flat support may damage and inactivate the single molecule [29] . However, in tapping mode, taking advantage of an oscillating tip minimizes the lateral shear forces between the probe and the sample, and therefore provides high-resolution visualization of samples with loose substrate adsorption properties [1] .
Review of the results
In situ AFM studies of prepared Aβ solutions on mica substrate have revealed sequential formation of globular amyloid aggregates, protofibrils and fibrils [5, 58] . We have summarized the dimensions of these species, as reported in different AFM studies, in Table 1 . The globular shape of Aβ aggregates on mica is a sign of its amphipathic character against a hydrophilic surface (such as mica). Lambert and coworkers [67] referred to these globular aggregates as amyloid derived diffusible ligands (ADDL). They described ADDL as a synthetic Aβ derivative produced from Aβ monomers under special conditions of inhibited or delayed fibrillization process [67] . They also reported on the high toxicity of ADDLs even at nanomolar concentrations [67] . However, there are still contradictions on the existence of ADDLs both in normal brains and in the brains of AD patients [37, 67] .
Shirahama et al. first described Aβ protofibrils in 1967 through an electron microscopic study [121] . The height differences between Aβ protofibrils and fibrils are more easily distinguishable in AFM studies than the studies using electron microscopy [47] (see Fig. 6 and Table 1 ). Amyloid protofibrils are transient intermediates of the Aβ fibrillization pathway; they are soluble and the dimensions of their earliest species are consistent with the dimensions of ADDLs [5] , as discussed above. According to AFM studies, protofibril assembly has two steps: initiation and elongation. These steps are distinct and could be individually inhibited or observed [47] . Elongation is a bidirectional process, which is achievable by addition of monomers, aggregates and small protofibrils to the end of core protofibrils [11, 47] .
The different behavior of amyloid protofibrils in contact with hydrophilic mica and hydrophobic graphite, has confirmed the hydrophobic nature led to the observation of the two-strand twisted ribbons, a finding unachievable by standard AFM tips [89] .
Single molecule fluorescence microscopy
Investigation into the molecular changes and intermolecular interactions of proteins is a challenging problem in protein misfolding diseases, such as AD. At present, we can perform measurement and study of molecular changes occurring in nanoscale by using a number of techniques. Fluorescence resonance energy transfer (FRET) microscopy is one such technique, which is applicable, both, for in vitro and in vivo systems [117] . FRET is in reference to an energy transfer mechanism between two chromophores. A chromophore is a region in a molecule where the energy difference between two of its different molecular orbitals falls within the range of the visible spectrum. In practice, FRET is the physical process of energy transfer from an excited donor fluorophore to a nearby acceptor fluorophore. The donor fluorophore could become exited by incident light [117] . This energy transfer depends on the distance between the donor and the acceptor fluorophores [112] . The mechanism of such an energy transfer is not radiation, but it is a result of intermolecular long-range dipole-dipole coupling [112] . Recently FRET microscopy became more applicable in biological investigations due to identification of some new fluorescence dyes, such as GFP (green fluorescent protein), which is an autofluorescent protein, and development of some novel optical methods [117, 112] . Applications of single-molecule FRET methodology mainly include investigation into structural dynamics of an individual protein molecule, monitoring its behavior at different folding conformations and revealing the mechanism of its interactions with the neighboring molecules [136] .
Recent AD applications of FRET include several diverse studies on abnormal protein species of AD pathogenesis. These studies uncovered several mechanistic relations between different molecular and submolecular actors in the AD pathogenesis. We analyze and report the results of two such studies below:
(i) According to NMR studies, Aβ 14−23 fragment assumes parallel β-sheet topology when incorporated in the polymerizing Aβ [8] , although inherently anti-parallel β sheet topology is preferred for this fragment. In a study reported by Shi et al. [120] , the FRET method was used in exploration of the mentioned topology shift that occurs on the Aβ 14−23 fragment when incorporated in longer fragments. Aβ 14−23 fragment is referring to a fragment of Aβ between amino acids 14 and 23. The common form of Aβ has 40 amino acids. β-sheet is referred to a generally twisted-pleated sheet like conformation of proteins, known as the second form of regular secondary structure in proteins (the first form is the alpha helix). This structure may assume two different topologies known as parallel and anti-parallel β-sheet topologies, depending on the direction of its consisting β-strands.
In the studies of Shi et al. FRET was also used to reveal the role of specific amino acids in the aggregation of Aβ. This knowledge could help with the Aβ anti-aggregation drug discoveries [120] . (ii) The FRET technique, in combination with a double immunofluorescence approach, was used by Kinoshita et al. in order to investigate the subcellular localization of AβPP and its interactions with human AβPP cleaving enzyme (known as β-secretase, or BACE) [60] . BACE is a membrane-anchored protease that produces "amyloid-β protein precursor β" (AβPP β ) and a fragment of 99 amino acids through its proteolytic cleavage activity on AβPP. The studies of Kinoshita et al. put more emphasis on the interaction between AβPP and BACE on the cell surface. Furthermore, they suggested that FRET approach might be of use for screening the potential therapeutics targeted to block AβPP/BACE interaction [60] .
The aforementioned studies are only a few examples of numerous FRET completed and ongoing studies, which are rapidly clarifying the way through which several different molecules cooperate to create a complex disorder like AD.
NanoSIMS microscopy
The effect of neurodegeneration in the brain tissue is not limited to morphological changes, but it also includes chemical elemental alterations [105] . These chemical elemental alterations in neurodegeneration are both in the total level of chemical elements and more importantly in the subcellular distribution of these elements [105] . The conventional histological microscopy methods including visible light microscopy and electron microscopy do not offer information about these chemical changes. NanoSIMS is a new type of "secondary ion mass spectroscopy" (SIMS), capable of highly sensitive and simultaneous detection of five elements at 50-200 nanometer spatial resolution (subcellular resolution) [105] . The five elements are N , P , S, Fe and Ca.
Quintana et al. [105] recently studied the usefulness of NanoSIMS microscopy for imaging the chemical as well as morphological alterations of pathological brain areas. Their studies also showed the distribution of iron, hemosidrin and feritin in the hippocampus of brain of AD patients. In addition, NanoSIMS visualizes the senile plaques with higher resolution (in CN-and Smaps) than optical imaging as shown in Fig. 9 [105] . Quintana et al. also recorded the distribution of the five elements N , P , S, Fe and Ca in the senile plaques, glial cells and pyramidal neurons [105] . The contrast shown in the SIMS images presents the distribution of chemical elements. However, NanoSIMS microscopy does not measure the concentration of chemical elements directly [105] .
NANODIAGNOSTICS FOR ALZHEIMER'S DISEASE
Presently, the prevailing common aim in the AD community is early detection for more timely and effective treatment of the disease. An ideal diagnostic tool for AD must have more than 80% sensitivity and al. [92] developed a nanoparticle oligonucleotide biobarcode assay capable of detecting concentrations of protein biomarkers several orders of magnitude lower than the concentrations detectable by conventional Enzyme-Linked ImmunoSorbent Assay (ELISA) technique [33] .
This high sensitivity of the bio-barcode assay is due to using engineered gold nanoparticles that carry the specific antibody of the target biomarker and hundreds of DNA barcodes simultaneously. Therefore, a single molecule of biomarker can be traced by hundreds of DNA barcodes [36] . Moreover, these DNA barcodes can be additionally amplified by the polymerase chain reaction (PCR) technique (See Table 2 and Fig. 10 ) [58] .
Furthermore, the bio-barcode assay approach is capable of simultaneous detection of several protein biomarkers, and therefore could be a sensitive technique for detection of a specific kind of dementia like AD among other differential diagnoses [58] . This potential of bio-barcode assay makes it also possible to determine the disease stage according to the concentration of different biomarkers.
Recently, Georganopoulou et al. reported a highly sensitive detection of ADDL in the CSF samples of AD patients through bio-barcode assay [36] . The results of this study show a significant difference between concentrations of ADDL in AD diagnosed subjects and in age-matched healthy controls. The ADDL concentration medians of these two groups have been reported as 1.7 fM and ca. 200 aM respectively [36] . This proves a correlation between increased CSF concentrations of ADDL and affliction with AD.
In conclusion, bio-barcode assay could provide highly sensitive and specific detection of pathology related biomarkers of AD in the CSF [36] . In comparison with common biomarker detection techniques like ELISA, the bio-barcode assay is a million times more sensitive [33, 54] . Moreover, when comparing with currently available imaging techniques for diagnosis of AD, bio-barcode assay is less expensive, faster and more efficacious [36] . However, it requires the invasive and unacceptable procedure of lumbar puncture, if CSF biomarkers are targeted.
Further studies are required to make the clinical usage of bio-barcode assay practical for screening and detection of AD. To achieve this it would be necessary to develop an accurate bio-barcode assay for detection of AD plasma biomarkers [53] .
Localized surface plasmon resonance (LSPR) nanosensor
The principle behind localized surface plasmon resonance (LSPR) nanosensor is to use singular optical properties of triangular silver nanoparticles (SNPs) as shown in Fig. 11 . The especial optical properties of triangular SNP include the ultra sensitivity of their peak extinction spectrum (λ max ) to nanoparticle size, shape and local external dielectric environment.
The sensitivity of silver nanoparticles λ max to their external nanoenvironment is the essence of signal transduction in the LSPR nanobiosensor [42] . In this method, any changes in the triangular SNPs external nanoenvironment will lead to a change in the local refractive index (caused by the adsorbed analyte, e.g. Anti-ADDL antibody). This change subsequently changes the SNPs' λ max , because of the sensitivity of triangular SNPs λ max to their external nanoenvironment. The change in SNPs λ max could be visualized through spectroscopy (see Fig. 11 ) [41] . Importantly, the LSPR nanobiosensor is sensitive to different concentrations of target biomolecule (ADDL in this case) since the solution concentration directly changes the local refractive index. Therefore, different wavelength shifts for different concentrations are detectable [41] . (see Table 2 ).
Beside to its high sensitivity and specificity [42] , LSPR nanobiosensor has simple and inexpensive components [42] . In addition, LSPR nanobiosensor has ex vivo instrumentation; therefore, it does not intervene with the integrity of body tissues except for sampling the appropriate body fluids. In this way, the invasiveness of the test only depends on the invasiveness of the sampling procedure. CSF sampling makes the test an invasive diagnostic method, as it requires lumbar puncture procedure.
The designer team of this technology, Haes et al., undertook several experiments on different biomarkers as well as ADDL [41] . They suggested three applications for LSPR nanosensor in AD. These applications are as follows: 1) Studying the oligomerization of the Aβ in ultra low concentrations, similar to concentrations of in vivo conditions, 2) Screening patients for AD, and 3) Studying the interactions between the pharmaceutics and their target molecules in drug discovery [41] .
Other possible nanotechnology methods
In addition to the two methods mentioned above, there are several other nanotechnology methods [54] that could have efficacious results in the route towards earlier and more sensitive and specific diagnosis of AD. Quantum dots, nanomechanical cantilever arrays, PEBBLE nanosensor, laser nanosensor, and nanoshell technology are the primary candidates of the alternative nanotechnology methods.
Quantum dots
Quantum dots (QD) are nanoscale semiconductor crystals with a fluorescent response to absorbed light. Their special fluorescent properties give them an advantage over using conventional fluorescent dyes [54] . Some of these special properties include: (i). Min-imal photo bleaching; (ii). Optimal stability; (iii). High signal to noise ratio; (iv). Broad absorption spectrum with very narrow, but size-dependant, tunable emission spectrum; and (v). Proper surface for biofunctionalization [100] . Overall, these properties give QDs the potential for long-term tracking and simultaneous visualization of multiple molecular events (either physiological or pathological) both in vitro and in vivo [57] .
The broad absorption spectrum and highly narrow emission spectrum of QDs enables the synchronic excitation of several QDs with different emission spectrums each specifically functionalized to track a certain biological process or mark a specific pathological biomarker [34] . This "simultaneous multiple labeling" property is especially important for diagnosis of AD, as discussed before.
However, due to the toxicity of the semiconductor materials presently used in QDs, like cadmium selenide (CdSe) and cadmium sulfate (CdS), their in vivo applications are questionable. Of course, some investigators have reported the safety of QDs in efficacious, but extremely low concentrations for labeling applications [87] , and others have shown insignificant biological activity and toxicity of QDs encapsulated in polymers (like phospholipids) [24] . Nevertheless, there is the question of whether the polymer coating of the QDs is sufficiently stable to prevent them to become toxic, especially for long term applications.
Nanomechanical Cantilever arrays
The original design of nanomechanical cantilever arrays was for the detection of oligonucleotides in biological samples. The micromechanical cantilever arrays have additional applications in proteomics.
Principle behind these sensors is due to their high sensitivity for detections of surface stress named as "nanomechanical detection". In addition to high sensitivity, these cantilever arrays are fast in response and they are highly specific to analyte. These nanosensors could be used for precise detection of several AD biomarkers in the CSF, including Aβ40, Aβ42, τ and phosphorylated-τ proteins. More importantly, their application for detection of ultra low concentrations of AD biomarkers in plasma could be fruitful [53] . Since analysis of plasma for AD biomarkers only requires the minimally invasive procedure of blood sampling, it is preferred over CSF analysis. Altogether, one may envision the application of nanomechanical cantilever arrays for a synchronic, highly sensitive and specific evaluation of plasma biomarkers of AD. This could bring the accurate early detection and screening of the AD to reality.
ALZHEIMER'S DISEASE THERAPY THROUGH NANOTECHNOLOGY
Presently there exist no therapeutic methods available for curing AD [84] . The cure for AD would require therapeutics that will cease the disease progress and will reverse its resultant damages. Today, common medications for AD are symptomatic and aim at the disrupted neurotransmission between the degenerated neurons. Examples of such medications are acetylcholine esterase inhibitors, including tacrine, donepezil, rivastigmine and galantamine [83] .
With further research, mechanistic therapeutic approaches could gradually complement the abovementioned medications. Design of each mechanistic therapeutic is for targeting a different stage of the AD pathogenetic process and therefore help to cease the progress of the disease [83] .
Presently there are the following five molecular mechanistic therapeutic approaches under investigation [46, 83] 
: (i). Inhibition of Aβ production; (ii). Inhibition of Aβ oligomerization, (iii). Anti-inflammation, (iv). Cholesterol homeostasis modulating; and (v).
Metal chelation. Meanwhile, advances in nanotechnology are adding further opportunities for the AD therapy.
Generally, the focus of the nanotechnology therapeutic approaches for every disease have been on drug discovery and monitoring [55, 78] , controlled release of therapeutic agents [91, 128] , and targeted drug delivery. The later is the most researched one, and it is especially prerequisite for reaching stronger therapeutic effects with the least amount of side effects. These applications are quite remarkable and challenging in respect to diseases of the CNS and brain. The subject of targeted drug delivery, for example, is appreciably complicated for CNS, due to the additional obstacle of the blood brain barrier (BBB) against the entry of a variety of molecules into the CNS tissues. With respect to drug discovery and monitoring, the histological complexity of CNS is a restricting factor [126] . However, the potential capabilities of nanoparticles and nanodevices, including their controllable size and suspendability (based on modifiability of the nanoparticles outer layer), multi-functionality [85] and remotecontrolled functionality [63] show promise in overcoming the CNS restrictions. Nevertheless, there are many challenges regarding the biocompatibility of nanoparticles and nanodevices especially in a complex biological milieu like brain with a huge concentration of cells and intercellular communications [126] . Presumably, the neuroprotective effect of fullerenols is due to both antioxidant reactions and inhibition of Aβ42-induced Ca 2+ neurotoxicity [50] . Huang et al. validated the latter finding in their investigation into the effect of fullerenol-1 upon Aβ-induced Ca 2+ influx in the cultured neurons [50] . Moreover, Dugan et al. have shown that fullerene poses complete neuroprotective properties against NMDA receptor mediated neurotoxicity [25] . NMDA receptor function is important to neuronal mechanisms of learning and memory. Altogether, applications of functionalized fullerene derivatives including carboxyfullerene and hydroxyfullerene (fullerenols), are promising in discovery of new drugs for AD; however further research on their pharmacodynamic and pharmacokinetic properties is necessary.
Anti-amyloid protections
Nanotechnology has recently offered some antiamyloid neuroprotective approaches against the cellular and synaptic toxicity of oligomeric and fibrillar (polymeric) Aβ species. The current ongoing nanotechnology research categories on anti-amyloid neuroprotective approaches are the following three: (1) Prevention from assembly of Aβ monomers (2) Breaking and resolubilization of the oligomeric or fibrillar (polymeric) Aβ species (3) Prevention from toxic effects of Aβ.
An example for the anti-assembly strategy is the work of Ikeda et al. [51] . They designed an amphipathic nanogel to mimic the function of molecular chaperons. These nanogels, similar to natural chaperons, incorporate proteins and control their folding and aggregation [51] . In examining the described potentials of nanogels against amyloidogenesis process, Ikeda et al. showed that nanogels could effectively incorporate Aβ and inhibit the amyloidogenesis process (Fig. 14-C) [51] . The nanogel (hydrogel nanoparticles) designed by Ikeda et al. was composed of cholesterol bearing pullulan (CHP). Pullulan is a natural water-soluble polysaccharide polymer consisting of maltotriose (a trisaccharide consisting of three glucose molecules linked with 1,4 glycosidic bonds) units [51] . CHP is formed from a backbone of polysaccharide and hydrophobic cholesteryl moieties (Fig. 14-A, B) [95] . It is noteworthy that the diameter of nanogels was 20-30 nanometers and each nanogel particle could incorporate 6-8 Aβ molecules (Fig. 14-B, D) [51] . Generally, since this technique prevents assembly at the monomer level it prevents Aβ from oligomerization. Therefore, anti-aggregation (i.e. anti-assembly) effect of CHP nanogels could be of therapeutic value for AD, by reducing the concentration of toxic Aβ oligomeric species.
Podolski et al. demonstrated that the hydrated fullerene C 60 has anti-assembly effect on the fibrillization of Aβ 25−35 fragment [103] by using transmission electron microscopy. The results of animal experiments for this effect of hydrated fullerene C 60 have suggested its potential to be used for producing new drugs for AD in human [103] .
Recently, a multipurpose anti-amyloid strategy was suggested for dendrimers [62] , which are considered as one of nanotechnology building blocks [79, 81, 82, 106] . Dendrimers are macromolecular structures with globular shape and a densely packed surface (Fig. 15-A) [62] . Their structure has offered them a number of biomedical potentials [82, 93] . Anti-assembly strategy of dendrimers can be performed either via their binding with peptide monomers (Fig. 15-C1 ) or through blocking the end of protofibrils and fibrils (Fig. 15-C2) [62] . These anti-assembly effects of dendrimers take place at their higher concentrations. However, Klajnert and coworkers suggested that the higher concentrations of dendrimers will have toxic effect rather than therapeutic results [61] ; because in higher concentrations, antiassembly effect of dendrimers happens and prevents Aβ fibrillization and thereby results in the accumulation of toxic low molecular weight Aβ oligomers. Nevertheless, low concentrations of dendrimers are supposed to have therapeutic effects, according to their effect on lowering the oligomeric species lifetime. This is because low concentrations of dendrimers induce Aβ oligomers to form less toxic fibrillar species [61] .
Resolubilization of fibrillar amyloid species is the basis of some other nanotechnology research approach- es on anti-amyloid protections. Recently, Kogan et al. utilized a combination of weak microwave fields and gold nanoparticles in their design for a remote amyloid dissolving technique. Their design was founded on dissolving Aβ aggregates and prevention from further aggregations through a highly concentrated thermal energy [63] . The thermal energy was produced from a low gigahertz electromagnetic energy source (microwave) by the gold nanoparticles, which are already attached to the specific target (i.e. Aβ). Gold nanoparticles are selected for this experiment because of their nanometric size, high surface-to-volume ratio, biocompatibility, high electron density and mobility [63] . These properties make it feasible to provide a specific bond target with a selective supply of energy in a remotely controlled manner, and without any adverse effects on the molecular proximity. Each Au nanoparticle provides a dissipating power of 10 −14 J/s that allows them to break a fibril bond (10 −20 J binding energy per bond) per microsecond without breaking covalent bonds, which are two orders of magnitude stronger [63] . However, careful consideration must be given to cytotoxic effects of Aβ oligomeric species. Therefore, the targeting must be arranged exclusively for these species. Otherwise, if the fibrillar species are targeted conversely, the toxic effects will increase due to an accumulation of Aβ oligomeric species following the breakdown of the fibrillar species. Considering the above-mentioned technical setting, the method of Kogan et al. seems to be advantageous for noninvasive investigation and manipulation of Aβ aggregates in AD.
Prevention from cytotoxic effects of Aβ is another prospect of nanotechnology for the anti-amyloid approach. Application of the modified dendrimers is a recent suggestion for this approach. Patel et al. demonstrated that dendrimers (both conjugated and unconjugated) could shield the cell membrane against Aβ membrane mediated neurotoxicity, which is due to Aβ electrostatic interaction with the cell membrane [99] . In addition, dendrimers can sequester the Aβ toxic species (Fig. 15-B) and therefore block their pathological effects on the cell membrane. However, because of the probable toxic effect of dendrimers on cells, this method needs further investigation for in vivo application [99] .
Interestingly, Memantine, a newly FDA approved neuroprotective drug against AD pathogenesis [35, 83, 107] , is a derivative of adamantine (1-amino-3,5-dimethyladamantane), which is a diamondoid. Diamondoids are cage like saturated hydrocarbons, known as one of the nanotechnology molecular building blocks [79, 81, 82, 106] . Nanotechnology molecular building blocks are used for building desired nanoobjects with specific properties in a controlled and engineered manner [79, 81, 82, 106] . Memantine, a derivative of adamantane, is beneficial for treatment of moderate to severe AD. Memantine could be prescribed if there is no therapeutic response to acetyle choline esterase inhibitors [35, 107] . Presumably, the main mechanism of memantine is uncompetitive NMDA receptor antagonism, and therefore inhibition of excitotoxicity of excessive glutamate neurotransmissions [107] .
Neuroregeneration
The neuroprotection strategies cannot result in a complete cure for AD. This is because they are restricted to protecting neurons from further damage and degeneration. Therefore, only the progression of the disease lesion and symptoms will slow or ideally stop [12] . However, the degenerated nervous tissue remains and the resultant functional loss of the brain does not recover from these medications.
A very complex challenge of drug discovery for neurodegenerative diseases is designing methodologies for replacing the dysfunctional and degenerated nervous tissue with new and functional neurons. In order to restore the cognitive function of the AD patient's brain effective neuroregeneration must take place in the injured areas of the brain. In this regard, drug discovery in such disorders like AD must concern solutions for neuroregeneration as well [59] .
Recent application of the stem cells technology in the problematic issue of neuroregeneration has suggested some solutions to reach a complete cure for AD [129, 141] . According to recent evidences, some specific regions of CNS possess neuronal regeneration potentials far more than the limited regeneration capacity of the other regions of the CNS tissue [137] . These regions (including the dentate gyrus of the hippocampus, the subventricular zone, the striatum and the substantia nigra) have a higher concentration of neuronal progenitor cells [137] . It is proposed that this potential could become the basis of neuroregeneration strategies in the treatment of neurodegenerative disorders [137] . However, the sufficiency of the innate neuronal progenitor cells for treatment of neurodegenerative disorders is questionable [146] . On the other hand, replacing cells that are derived from "embryonic stem cells" have been suggested as a more reliable strategy for regeneration of the CNS tissue in senile neurologic disorders, such as AD and Parkinson's disease [146] .
Currently, in the area of neuroregeneration, application of nanotechnology on axonal regeneration after traumatic insult is promising [28, 124] . In addition, nanotechnology is helping to increase the performance of stem cell technology in several areas [3, 125] . However, at present studies aimed at overcoming the challenges of stem cell therapy for degenerative disorders such as AD are rare. Attempts that take advantage of the potentials of nanotechnology may surmount the stem cell therapy challenges for AD, and therefore may bring us to a complete cure for this debilitating disease in the future.
Drug delivery systems
Generally, penetration of drugs into the brain is strictly limited. Without exceptions, large pharmaceutics are unable to cross blood brain barrier (BBB). More interestingly, only less than 2% of small molecules can cross BBB [97] . All therapeutics aimed to a target in the brain must have a group of specific characteristics for crossing BBB, including small size, lipophilicity, and compactness (measured from polar surface area) [89] .
Nanotechnology can improve the efficacy of some potential therapeutic agents for CNS diseases including AD by facilitating their delivery across BBB. For instance, nanoparticle technology applies solid colloidal nanoparticles (ranging from 1nm to 1000nm in size) to disguise the limiting characteristics of potential therapeutic agents in order to enable their transport across BBB [75] . Moreover, nanoparticle technology retards drug release in the brain and decreases the peripheral toxicity [75] .
Recently two studies have prepared a nanoparticle carrier for the model drugs thioflavin T and thioflavin S [48, 123] . This nanoparticle carrier is composed of a polystyrene core and a PBCA [poly (butyl-2-cyanoacrylate)] shell with a diameter of 90-100 nm. The gradual enzymatic degradation of PBCA shell allows a controlled and long-term drug delivery in the brain [48, 123] . The results show selective targeting of fibrillar Aβ after intracerebral injections to APP/PS1 mice with age dependent β-amyloidosis. These studies could be suggestive of potential benefits of core-shell nanoparticles for prevention of Aβ accumulation or for acceleration of Aβ clearance, as well as sending Aβ sensitive detectors beyond BBB [48, 123] .
Some investigators have recently designed other nanoparticle carrier systems for metal chelation agents. Metal chelation therapy is a therapeutic approach for the AD that reduces the cellular oxidative stress [74] . This approach is based upon the effects of dis-homeostasis of metallic ions on triggering the oxidative stress in the AD pathogenesis. In studies undertaken by Liu et al. an efficient chelator nanoparticle system (CNPS) was prepared [74] . In these studies, Desferrioxamine, an FDA approved metal chelator, was used. Nanoparticles were conjugated with Desferrioxamine through an amido bond between a primary amino group in the chelator and a carboxyl group on the nanoparticle surface [74] . Liu et al. demonstrated that the chelation effect of metal chelator was retained after formation of CNPS. This work shows other advantages of nanoparticle technology in addition to feasibility of carrying iron chelators across BBB. For instance, it was suggested that one reasonable mechanism for nanoparticle mediated BBB transport could be the ability of nanoparticles to preferentially bind to Apo E [73] . On the other hand, it was shown that the iron chelated CNPS was able to traverse the BBB in the reverse direction by preferential adsorbtion of Apo A-I and thereby removal through LDL transport system. Moreover, it was suggested that the inherent toxicity of the chelators are obviously decreased after conjugation with nanoparticles [73] . Similarly, in the study of Cui et al. [20] d-penicillamine, an FDA approved drug for chelalation of copper in Wilson's disease, was examined as a metal chelator in AD. They conjugated d-penicillamine with the nanoparticles containing MPB-PE and PDP-PE. This conjugation enabled the traverse of d-penicillamine through the BBB in spite of its highly hydrophilic properties. This study showed the ability of d-penicillamine and EDTA for chelating copper and disolubilizing Aβ42 [20] . Interestingly, it was demonstrated in this study that the BBB integrity and permeability remained unchanged and no changes in the cerebral perfusion flow were evident; therefore it is suggested that the transport mechanism for this nanoparticle formulated carrier system is endocytosis, transcytosis or passive diffusion in the absence of barrier opening [20] .
As we reviewed before, a large portion of AD pathogenetic mechanism happens inside the cells. These intracellular mechanisms mainly include oxidative stress, the formation of PHF and NFTs and intracellular oligomerization of Aβ. Generally, if a therapeutic agent is designed to interrupt such intracellular pathologies in the brain tissue, it must be delivered into its target cells in addition to being delivered to the brain tissue. Nevertheless, there are a set of obstacles against the entry of a therapeutic agent into cytoplasm. Recently, B.T. Shea et al. have designed an especial nanosphere to deliver vitamin E to human neuroblastoma cultured cells, which have been already exposed, to Aβ [118] . In this study polyethylene glycol (PEG)-based nanosphere was used for encapsulatation of vitamin E in order to facilitate its entrance to the cytosol. Results indicated an improvement of vitamin E efficacy against Aβ induced oxidative stress [118] .
CONCLUSIONS
AD is the primary common dementia syndrome world wide, with an astronomical devastating socioeconomic burden on society. Solving the major problems of early diagnosis and effective cure for AD requires interdisciplinary research efforts. Research on the basic pathogenetic mechanisms of the disease has provided new insight for designing diagnostic and therapeutic methods. However, the need for further studies on the exact root causes of AD is still palpable.
Studies into molecular mechanisms
Applications of nanotechnology methods in studies on the molecular mechanism of AD are promising:
(1) Through AFM, studies on a number of direct in vitro observations of the main pathological structures of AD, Aβ species and τ -protein are accomplished. Using the AFM tapping mode operation and applying multi-wall carbon nanotubes as the AFM tips has enabled high-resolution visualization of Aβ and τ during their related chemical processes [142] . The results illuminate the mechanisms of these key processes in AD and the structural properties of their involved molecules. (2) Through single-molecule FRET (fluorescence resonance energy transfer), which is applicable both in vivo and in vitro, studies into the submolecular and intermolecular interactions of abnormal protein species in AD pathogenetic process [112, 117] has been achieved. (3) In addition, using NanoSIMS microscopy has enabled investigation into subcellular chemical elemental changes during the AD pathogenesis [105] .
However, few published in vivo studies have investigated the molecular processes of AD pathogenesis. It is expected that other nanotechnology methods will accelerate such studies in the future, for example through biologically stable markers (e.g. functionalized quantum dots) transcended beyond the BBB.
Early diagnoses
Development of a nanotechnology approach for the early diagnosis of AD is quite promising. This is because of the potential for development of multifunctional nano-sensors for simultaneous detection of ultra low concentrations of different biomarkers. The lack of one specific biomarker for AD and the ultra low concentrations of the group of AD biomarkers highlight the need for such multifunctional nano-sensor.
Lambert et al., performed in situ AFM studies on ADDL (amyloid derived diffusible ligands), a synthetic Aβ derivative produced from Aβ monomers. They emphasized on the possibility of in vivo existence of ADDL [67] . There is now a general consensus on the neurotoxicity of ADDLs [17, 37, 67, 139] , and it has become the choice biomarker in recent nanodiagnostic studies for AD [36, 41] .
The CSF (cerebral spinal fluid) analysis for the AD biomarkers has a higher degree of accuracy and can show brain tissue damages earlier than the known plasma biomarkers associated with the AD. However, the in vitro CSF analysis requires the invasive procedure of lumbar puncture for obtaining a sample. In this regard, a common deficiency of the proposed nanotechnology methods for detection of AD, thus far, is that they are limited to in vitro investigations of the CSF samples. Such nanotechnology methods include the bio-barcode assay and the LSPR techniques.
Nanotechnology has the potential to provide us with other tools that may be applicable for ultra sensitive detection of the AD biomarkers in plasma (e.g. nanomechanical cantilevers in vitro and quantum dots in vivo) or for in vivo investigations following parenteral administration, and thereby providing minimally invasive methods for early diagnosis of AD.
An ultimate goal for very early detection of an underlying AD pathology would be the development of a safe and implantable nanoscale biosensor for prolonged monitoring of AD biomarkers in the CSF. Such a sensor must be able to transmit any biomarker detection event to an external device that records the transmitted signals and reports an estimated amount for the concentration of AD biomarkers in the CSF. Of course, in order to send such biosensor to a place exposing with CSF, it is necessary to design noninvasive approaches.
Effective treatment
The current medical approach has been to lower the symptoms of the AD. Although, the resultant therapeutics are unable to resolve the root causes of the disease [49, 86] , they have offered many economic benefits. However, there are still possibilities for designing more potent but cost effective diagnostic and therapeutic approaches. These possible approaches could become more efficient if taking advantage of the nanotechnology potentials and the vast amount of information currently available about the molecular causation of the disease. Targeted drug delivery and prolonged drug release are the two major potential benefits of application of nanotechnology in designing more potent therapeutic agents for the AD.
Designing especial nanoparticles targeted to molecules with more initial role in AD pathogenesis is of high importance in effective drug discovery for AD (Fig. 12) . Some recent studies have taken advantage of nanotechnology for a neuroprotective approach against AD pathology. For instance, neuroprotective effects of some simple nanomaterials including fullerenes, dendrimers and diamondoids (the root of FDA approved memantine) [25] [26] [27] 61, 103, 106] , and complex nanosystems like nanogels (as artificial chaperons) [51] have been evaluated and confirmed in these studies.
En route to making AD a curable disease, we must design drugs and methods for CNS regeneration. It must become possible to replace the dead nervous tissue in order to regain the brain function and completely cure the afflicted patients. We are still at the very early stages of such an ambitious project. However, the increasing abilities offered by the combination of nanotechnology and some other novel approaches like stem cell technology could bring about a promising cure for AD. 
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